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Abstract
Background: The objective of this research was to evaluate data from a randomized clinical trial that tested injectable
diacetylmorphine (DAM) and oral methadone (MMT) for substitution treatment, using a multi-domain dichotomous index, with
a Bayesian approach.
Methods: Sixty two long-term, socially-excluded heroin injectors, not benefiting from available treatments were randomized
to receive either DAM or MMT for 9 months in Granada, Spain. Completers were 44 and data at the end of the study period
was obtained for 50. Participants were determined to be responders or non responders using a multi-domain outcome index
accounting for their physical and mental health and psychosocial integration, used in a previous trial. Data was analyzed with
Bayesian methods, using information from a similar study conducted in The Netherlands to select a priori distributions. On
adding the data from the present study to update the a priori information, the distribution of the difference in response rates
were obtained and used to build credibility intervals and relevant probability computations.
Results: In the experimental group (n = 27), the rate of responders to treatment was 70.4% (95% CI 53.287.6), and in the
control group (n = 23), it was 34.8% (95% CI 15.354.3). The probability of success in the experimental group using the a posteriori
distributions was higher after a proper sensitivity analysis. Almost the whole distribution of the rates difference (the one for
diacetylmorphine minus methadone) was located to the right of the zero, indicating the superiority of the experimental
treatment.
Conclusion: The present analysis suggests a clinical superiority of injectable diacetylmorphine compared to oral methadone in
the treatment of severely affected heroin injectors not benefiting sufficiently from the available treatments.
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Background
Opioid addiction is a chronic relapsing disease that affects
the lives of sufferers in very different ways [1]. Opioid-
dependent people continue using these drugs despite the
consequences for their health, legal situation, social inte-
gration and personal relations [2]. Opioid substitution
therapies (such as methadone, buprenorphine or diacetyl-
morphine) are intended to reduce illicit opioid use,
deaths, disease and crime, as well as to improve patients'
health, quality of life and psychosocial integration. There-
fore, the effectiveness of a treatment may be reflected in
different areas of patients' lives and as a consequence a
treatment can be evaluated in different ways.
Various studies have provided evidence of the effective-
ness, safety, viability and cost-effectiveness of prescribing
diacetylmorphine (DAM) for the treatment of long term
opioid-dependent persons who have not benefited from
other treatments [3-11]. DAM is currently prescribed, as a
regular programme or in the context of a clinical trial, in
six countries: the UK, Switzerland, the Netherlands, Ger-
many, Spain and Canada [12].
In the Dutch trial testing co-prescribed diacetylmorphine
vs. methadone for long-term opioid dependence, treat-
ment effectiveness was evaluated by means of a multi-
domain outcome index (MDO) in order to obtain an
overall measure of treatment success or failure [10,13].
The goal of the MDO is to assess response by means of a
dichotomous variable addressing, as a combined meas-
ure, different aspects involved in the process of stabilizing
drug-dependent patients: their physical and mental health
and psychosocial integration.
It has been remarked that although a MDO allows to cap-
ture the complexity of drug-dependence and summarizes
various measures by means of a single index, it does not
enable the weighting of each dimension making difficult
to evaluate in which particular aspects the patient has
improved; moreover, a MDO makes it more complicated
to perform comparisons with other studies [14,15]. The
first of these problems may be addressed by separating the
dimensions constituting the MDO, in order to determine
their individual performance, as we have done in a previ-
ous analysis [11]. The goal of the present study is to over-
come the second obstacle: we seek to evaluate the results
of the DAM prescription trial carried out in Andalusia
(Spain) with the multi-domain dichotomous index pro-
posed in the Dutch study [10]. Here we analyze data from
the Andalusian study by formally applying prior empirical
evidence reported on the evidence of this treatment. In
addition, we discuss the contribution of the results to the
state of the art.
Methods
We analyzed data from a randomized controlled trial
comparing injectable DAM vs. oral MMT conducted in
Andalusia, Spain, from February 2003 to December 2004.
Study design, methods and results have been published
elsewhere [11]. Briefly, 62 long-term, opioid dependent
individuals with severe health and other drug related
problems were randomized to receive either injectable
DAM (plus oral methadone) or oral methadone alone. A
total of 44 participants completed the 9 month treatment
period and 50 completed the follow-up evaluations.
For the present study we analyse data from the Andalusian
trial using a multi-domain outcome measure reported in
a previous study conducted in The Netherlands, also com-
paring injectable DAM and oral MMT [10]. The MDO is a
dichotomous index, imputing success when the patient
shows at least 40% improvement at 9 months, compared
to the baseline values, in physical health (MAP-H) [16], or
mental status (SCL-90)[17], or social functioning (illegal
activities and/or contact with non drug users), without a
deterioration superior to 40% in any of these dimensions
and no substantial increase (20%) in cocaine use. More
details about this MDO can be found elsewhere [13].
Statistical analyses were performed using a Bayesian
approach in order to take advantage of previous informa-
tion, a strategy highly appropriated when working with
small sample sizes (small samples are very common in tri-
als aimed at treating conditions with low-incidence in the
community). Previous information in big samples would
have virtually no impact in the results. We calculated suc-
cess rates, the relative risk (RR) and the respective 95%
confidence intervals (CI). Using data derived from the
Dutch study, a priori information was obtained for analy-
sis of the Andalusian study data using Bayesian methods
[18-21]. Analyses were performed by intention to treat,
with no imputation for missing values. We denote by θ1
the percentage of patients who responded to the experi-
mental treatment (DAM), while θ2 represents the percent-
age of those responding to the conventional treatment
(methadone). Bayesian analysis enables us to calculate
the probability of θ1 being greater than θ2 by a specified
magnitude, based on the data from our trial and prior
information from the Dutch trial. Upon clinical judgment
and based on the target populations (i.e. treatment-refrac-
tory opioid-dependent individuals) and outcome expecta-
tions (i.e. stabilization, long-term treatment), we assumed
as clinically relevant a minimal difference of 15% between
the rates of responders in each group, and assessed the
probability of this being fulfilled under different assump-
tions.
For each of the parameters θ1 and θ2 we selected three a
priori distributions from the family of beta distributionsTrials 2009, 10:70 http://www.trialsjournal.com/content/10/1/70
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with parameters a and b which approximately represent
the implicit number of responders and non-responders in
the prior distribution. These three scenarios represent dif-
ferent degrees of incorporation of prior evidence. In the
first scenario ('No use' of historical data) Jeffreys' priors
were used, which are non-informative prior beta distribu-
tions with parameters a = b = 0.5 for both, θ1 and θ2. The
remaining two pair of priors were set on the basis of the
knowledge derived from a previous clinical trial using
injected DAM. [10] The respective CI associated with these
prior data were calculated, and parameters were chosen (a
and b in the beta distribution) such that the maximum
density intervals of these distributions coincided approxi-
mately with the CI obtained previously. The second sce-
nario ('Partial use') down-weighted the Dutch study by
dividing a and b by 5. Finally, we repeated the process
using the values a and b without modification ('Full use'),
essentially equivalent to a full pooling of the trial results
in a meta-analysis.
In order to perform a sensitivity analysis, several scenarios
need to be imagined. The one considered when we do a
'partial use' of previous data is placed between two
extreme situations: no use of previous data (meaning
there are no similarities between contexts) and full use of
them (meaning both contexts are equal). These extreme
positions are extreme, since we cannot assume the Dutch
and Andalusian context are the same, or that they have
nothing in common either. The chosen halfway scenario
takes into account this argument. A division by 5 of the
parameters derived from the Beta-distribution was chosen
in order to substantially increase the distribution disper-
sion attributed to previous data, allowing an adequate
sensitivity analysis.
For each one of these prior choices, we obtained the con-
jugate beta distributions for the response rate in each arm
of the trial using our binomial data. A total of 20.000 sim-
ulations were made from these a posteriori distributions,
and the corresponding 20.000 differences θ1 - θ2 were cal-
culated providing an a posteriori distribution of the differ-
ence between the proportions: Δ = θ1 - θ2. This was used to
derive simulation-based estimates of the probability of
relevant magnitudes concerning Δ: P(Δ larger than 0), P(Δ
larger than 0.15) and a maximum density interval (prob-
ability interval for Δ) at 95%. EPIDAT 3.1 was used for all
computations [22].
Results
The  a priori beta distributions, as stated above, were
obtained using the data from the Dutch clinical trial. This
was carried out with a sample of 98 patients in the exper-
imental group (injectable DAM) and 76 in the control
group (oral methadone). Twelve month success rates of
56% and 31%, respectively, were obtained. To define the
above-mentioned informative a priori distributions, we
began by calculating the 95% CI (frequentist) associated
with the preceding data. Confidence intervals for the per-
centage of patients who responded to treatment in the
control and experimental groups in the Dutch trial were
(4666) and (2141) respectively; and the a priori beta dis-
tributions consistent with them were a1 = 55, b1 = 43, and
a2 = 24, b2 = 52 respectively. Following the steps described
in the methods section, the analysis was performed for the
three possible scenarios, as described in Table 1.
Among the patients in the experimental group (n = 27),
the rate treatment responders was 70.4% (95% CI
53.287.6), while for those in the control group (n = 23) it
was 34.8% (95% CI 15.354.3). The difference in response
rates between the two groups was 36.6% in favour of the
experimental group. The probability of a positive
response to treatment by participants allocated to experi-
mental group (RR) was 2.2 times greater than for those of
the control group (95% CI 1.24.3; p = 0.012). The number
needed to treat was 2.8 (IC 95% 1.610.0).
After using the data from the present study to update the
a priori information, the nonparametric distributions
obtained from the simulated differences in success rates
(experimental less conventional) in the 3 scenarios is
shown in Figure 1. This shows that the probability of suc-
cess in the experimental group is higher than in the con-
trol group. In the last two cases, the whole distributions
are located to the right of the zero, above the 6% level; in
the first one, the distribution includes a very small frac-
tion of negative values. The 95% probability intervals for
the difference and probabilities of Δ >0 and Δ >0.15 are
presented in Table 2.
Discussion
Our analysis of the Andalusian trial data using a multi-
domain outcome measure as a treatment response crite-
rion shows that the group receiving injectable diacetyl-
morphine had a greater probability of responding to
treatment than the group that receive only oral metha-
done, both in clinical and in statistical terms.
Table 1: a and b values for each parameter θ1 and θ2 among the 
three groups of the a priori distributions used.
Dutch information θ1 θ2
a1 b1 a2 b2
No use 0.5 0.5 0.5 0.5
Partial use 11.0 8.6 4.8 10.4
Full use 55.0 43.0 24.0 52.0Trials 2009, 10:70 http://www.trialsjournal.com/content/10/1/70
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The results obtained with this MDO are remarkable given
that this indicator has a high level of exigency, as much by
its complex definition, the magnitude of the demanded
change (40%) and by the inclusion of the criterion of the
cocaine consumption. Also, the MDO is a dichotomous
variable, being less sensitive to change than the dimen-
sional measures. For a fixed sample size a binary outcome
measure would be able to detect a change of a 10% of the
variance, whereas a dimensional measurement could
detect changes of 1% [23].
It is important to note that the results come from a small
sample and this limits their generalizability; other limita-
tions derived from the design of the study have been dis-
cussed elsewhere [11]. When comparing the present study
with the one conducted in the Netherlands [10], it should
be taken into account that the control group in the Anda-
lusian trial received larger average doses of methadone,
and also they received an optimized version of MMT
(involving greater psychosocial resources than the treat-
ment that is normally provided). Also, the intervention
lasted 12 months in the Dutch RCT, and 9 months in the
Andalusian one. Nevertheless, the differences between the
groups in the Dutch RCT stabilized after approximately 10
months.
In the present study the Bayesian analysis reveals a clear
superiority of the diacetylmorphine-based treatment over
methadone. The fact that the probability of the experi-
mental treatment surpassing the conventional one by at
Non parametric distribution of success rates differences between the experimental and control groups for the three possible  scenarios (without using the Dutch data in order to determine the priors with partial and total use) Figure 1
Non parametric distribution of success rates differences between the experimental and control groups for the 
three possible scenarios (without using the Dutch data in order to determine the priors with partial and total 
use).
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Table 2: Probability values of the difference in success rates 
between the experimental and control groups being bigger than 
0 and 0.15, and probability intervals (95%) for the possible three 
scenarios: without using the Dutch data in order to determine 
the priors, partial use, and total use).
Dutch information P(Δ>0) P(Δ>0.15) Probability Interval (95%)
No use 0.994 0.926 8.0  57.6
Partial use 0.998 0.934 9.9  50.4
Full use 1.000 0.965 13.9  39.3Trials 2009, 10:70 http://www.trialsjournal.com/content/10/1/70
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least 15% gives such a high result (over 0.9 in the different
scenarios) is important, especially considering the case in
which this value is derived from the formal integration of
earlier data with those from the present study. Our find-
ings fit in with the a priori probability of the superiority of
injectable DAM versus oral methadone in the case of treat-
ment-refractory patients, and show how even partial use
of the historical data reinforce the confidence in a clini-
cally relevant difference.
The results obtained using Bayesian analyses are similar to
those derived from the classical statistical approach when
large sample sizes are used. The Bayesian method used in
this analysis, however, was especially well suited because
of the small sample size in our trial; in addition, it allowed
to integrate previously obtained results into the current
study to a partial or full extent. Moreover, this method is
in agreement with recommendations of paying special
attention to calculating the magnitude of the effect of the
treatment being studied, and not so much on its statistical
power [24,25].
Conclusion
National and European data shows a stabilization in the
use of heroin. However, a sub-group of heroin users with
high health and social needs are not properly served by
the health care system. Pharmacological alternatives are
needed to attract and engage these individuals in treat-
ment. The evidence for the greater efficacy of injectable
DAM, in comparison with oral methadone, in the case of
long-term, treatment-refractory opioid-dependent
patients is supported by the present study and by others
[4-6,10,26,27]. The next step would be to design a study
evaluating the provision of DAM in standard clinical prac-
tice, i.e. in more ecological settings. However, the delay in
the approval of those programs still depends more on the
political and moral contexts than on the scientific conclu-
sions reached over recent years [12,28].
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